Cite
MLA Citation
M.D. Hellmann et al.. “3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC).” European journal of cancer, vol. 51, n.d., pp. S632–S633. http://access.bl.uk/ark:/81055/vdc_100030628321.0x000009